KN95 Masks Are Now Offered by AGE Industries

AGE Industries provides cost effective KN95 masks that are comfortable and protective

KN95 masks are now offered by AGE Industries. They are highly protective, comfortable and cost-effective.  The news was announced today.

KN95 masks feature 4-layer protection, a step above most masks on the market, which are 1 to 3 layers thick. Further, KN95 masks provide a striking 95% protection against all particles that are greater than 0.3 µm in diameter. This includes bacteria, viruses, pollution particles, fine particles, dust, smog, pollen, and more.
KN95s offer even more protection than cloth masks, confirms the CDC on their website. The CDC also provided an update on January 14th, 2022 removing concerns related to supply shortages for these masks, clarifying that people can in fact choose masks such as N95s and KN95s.
Currently approved by the WHO as a safety measure from COVID-19, these masks’ superior protection is the reason why they are used by healthcare providers, patients, and citizens across the globe. KN95 respiratory masks are also regulated by the Chinese government under GB2626-2006, GB262-2019, and GB19083-2010.
KN95 masks offer considerable comfort. They are skin-friendly and do not cause rashes or irritation. KN95 masks also have a 3D foldable design, ear loops, and a nose bridge, allowing them to provide excellent fitting and sealing. The ability for these masks to fit the form of your face leads to better protection and also reduces fogging in glasses. Most other masks on the market do not fit well, leaving gaps near the side of the face and the nose uncovered.
Providing packages at 20 masks per box and 50 boxes per case, AGE Industries can ship anywhere in the US, Mexico, and Canada and can also deliver globally via AGE Industries or one of its partners. AGE Industries is committed to providing these protective and comfortable masks at affordable prices to people around the world who need them.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version